The Dispersome® technology allows formulation of poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.
Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.
Some of our industry partners. We are delighted to have established partnerships with prominent pharmaceutical companies that have adopted our Dispersome® Technology. These valued collaborations underscore our commitment to advancing drug solubility, positively impacting patient well-being, and shaping the future of drug delivery.
Zerion Pharma is featured as an innovative start-up by Pharmaceutical Technology in their ‘Trends in Formulation 2023’ eBook, October 2023.
September 25, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces that the Company has elected Mr. Carl-Åke Carlsson as its new Chairman of the Board of Directors.
September 1, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces that the Company has strengthened its management team with the appointment of Dr. Mads Aaboe Jensen as Vice President Business
Xuezhi Zhuo, Vito Foderà, Per Larsson, Zarah Schaal, Christel A.S. Bergström, Korbinian Löbmann, Aleksei Kabedev. "Analysis of stabilization mechanisms in β-lactoglobulin-based amorphous solid dispersions by experimental and computational approaches”. European Journal of Pharmaceutical Sciences 2024, 192, 106639. https://doi.org/10.1016/j.ejps.2023.106639
Xuezhi Zhuo, Zeyneb Sener, Aleksei Kabedev, Min Zhao, Anis Arnous, Donglei Leng, Vito Foderà, and Korbinian Löbmann. "Mechanisms of Drug Solubility Enhancement Induced by β-Lactoglobulin-Based Amorphous Solid Dispersions." Molecular Pharmaceutics 2023, 20 (10), 5206-5213. https://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.3c00577
Leng D, Bulduk B, Widmer T, Wiborg O, Sanchez-Felix M, Löbmann K. "Protein based amorphous solid dispersions: a case study investigating different whey proteins at high drug loading." Pharmaceutical Research, 2023. https://doi.org/10.1007/s11095-023-03542-9
Leng D, Bulduk B, Anlahr J, Müllers W, Löbmann K. "Enhanced dissolution rate of nimodipine through β-lactoglobulin based formulations." International Journal of Pharmaceutics, 2023, 635, 122693. https://doi.org/10.1016/j.ijpharm.2023.122693
Xuezhi Zhuo, et al. "A Comparative Study between A Protein Based Amorphous Formulation and Other Dissolution Rate Enhancing Approaches: A Case Study with Rifaximin." Pharmaceutics 15.1 (2022): 126. https://doi.org/10.3390/pharmaceutics15010126
Kabedev A, Zhuo X, Leng D, Foderà V, Larsson P, Bergström CAS, Löbmann K. "Stabilizing Mechanisms of β-Lactoglobulin in Amorphous Solid Dispersions of Indomethacin." Molecular Pharmaceutics 2022, 19 (11), 3922-3933. https://doi.org/10.1016/j.ijpharm.2023.122693
Mishra J, Bohr A, Rades T, Grohganz H, Löbmann K. "Whey proteins as stabilizers in amorphous solid dispersions". European Journal of Pharmaceutical Sciences, 2019, 128, 144-151 https://doi.org/10.1016/j.ejps.2018.12.002
